Johnson & Johnson has recalled lots of its Simponi injections for possible substandard dosage of its arthritis treatment, according to a Reuters news report.
A Johnson & Johnson spokesperson said there are no quality issues regarding the actual medication Simponi. Rather, a defect in the device did not allow the full dose to be delivered for self-injection. The defect was detected in Germany during quality assurance checks. In total, 165 U.S. units have been recalled, according to the report.
Read the news report about the Johnson & Johnson recall.
Read other coverage about Johnson & Johnson:
- Smith & Nephew Shares Jump After Rejecting Johnson & Johnson Acquisition
- Alphatec Holdings Names Former Johnson & Johnson CFO as New CFO
- FDA Sends Johnson & Johnson Letter of Warning
A Johnson & Johnson spokesperson said there are no quality issues regarding the actual medication Simponi. Rather, a defect in the device did not allow the full dose to be delivered for self-injection. The defect was detected in Germany during quality assurance checks. In total, 165 U.S. units have been recalled, according to the report.
Read the news report about the Johnson & Johnson recall.
Read other coverage about Johnson & Johnson:
- Smith & Nephew Shares Jump After Rejecting Johnson & Johnson Acquisition
- Alphatec Holdings Names Former Johnson & Johnson CFO as New CFO
- FDA Sends Johnson & Johnson Letter of Warning